This morning in Amsterdam brought some interesting breast and ovarian cancer presentations that I thought deserved a quick recap – one is potentially practice changing in HER2 breast cancer and the other is a new product in development (Biomarin’s BMN 673) that is worth watching out for:

Posted by 

Purchase Access to Premium Content

Click on blue icon to purchase a PERSONAL, INDIVIDUAL license to premium content. You are NOT PERMITTED to share access or copies of posts. If you wish to purchase a CORPORATE or MULTI-USER license or want to be able to share content PLEASE CONTACT US to purchase this. Please read the terms of use before purchasing & if you work in PR, Communications or for an agency, the guidance within it. Rates may change without notice and are non-refundable.